POSSIBILITIES OF A COMBINATION OF DOCETAXEL WITH ANDROGEN DEPRIVATION IN INITIAL THERAPY OF HORMONESENSITIVE PROSTATE CANCER
https://doi.org/10.21518/2079-701X-2017-6-94-97
Abstract
Androgen deprivation therapy (ADT) is used in the treatment of prostate cancer metastatic cancer (PC) since the first description of its hormone dependence in 1941. After receiving the results of a TAX 327 study in 2004, the drug from the taxanes - docetaxel became the main cytostatic agent in the treatment of the castration resistant prostate cancer (CRPC). In a recently published
study CHAARTED it was shown for the first time that the combination of ADT with docetaxel in men with hormone-sensitive metastatic prostate cancer (HSMPC) showed the advantage in the total survival rate by 13.6 months compared to the independent ADT. Similar results were obtained in the STAMPEDE study of men with local-distrubuted and metastatic PC with initial long ADT. A combination of six docetaxel courses with ADT in men starting long-term ADT demonstrated the same advantage by the survival rate parameter compared to the standard ADT by 10 months. Based on the reliability of the treatment results obtained by a new combination of a cytostatic and hormonal product, docetaxel in addition to ADT should be regarded as the basic initial therapy for men with the first identified hormone-sensitive PC, as reflected in the practical recommendations on the treatment of malignant tumours (RUSSCO) 2016 and the recommendations of the European Association of Urologists, 2017.
About the Authors
A. A. GRITSKEVICH
Vishnevsky Scientific and Research Institute of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
S. V. MISHUGIN
Pletnev Municipal Hospital of the Moscow Healthcare Department
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
I. G. RUSAKOV
Herzen Moscow Scientific Oncologic Institute -Affiliate of the National Medical Research Centre of the Ministry of Health of Russia
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
References
1. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой М., 2017. С.12-36.
2. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 2004, 351(15): 1513-20.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004, 351(15): 1502–12.
4. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol, 2008, 26(2): 242–5.
5. Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol, 2014, 66(4): 646-52.
6. van Soest RJ, de Morree ES, Kweldam CF, de Ridder CM, Wiemer EA, Mathijssen RH, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration- resistant prostate cancer. Eur Urol, 2015, 67(6): 981-5.
7. van Soest RJ, van Royen ME, de Morree ES, Moll JM, Teubel W, Wiemer EA, et al. Cross- resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castrationresistant prostate cancer. Eur J Cancer, 2013, 49(18): 3821-30.
8. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med, 2015, 373(8): 737-46.
9. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley D, Spears MR, et al. Adding docetaxel and/or zoledronic acid for hormone-naive prostate cancer (STAMPEDE): survival results form an adaptive multi-arm multi-stage platform randomised controlled trial. Lancet, 2016, 387(10024): 1163-77.
10. Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, et al. Adding docetaxel or bisphosphonates to standard-of-care in men with localised or metastatic hormone-sensitive prostate cancer: a systematic review and metaanalyses of aggregate data. Lancet Oncol, 2016, 17(2): 243-56.
11. Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol, 2010, 28(30): 4562–7.
12. Kongsted P, Svane IM, Lindberg H, Daugaard G, Sengelov L. Low-dose prednisolone in first-line docetaxel for patients with metastatic castration- resistant prostate cancer: Is there a clinical benefit? Urol Oncol, 2015, 33(11): 494.
13. Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, et al. ELM-PC 4 investigators. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castrationresistant prostate cancer (ELM-PC 4): a doubleblind, multicentre, phase 3, randomised, placebo- controlled trial. Lancet Oncol, 2015, 16(3): 338-48.
Review
For citations:
GRITSKEVICH AA, MISHUGIN SV, RUSAKOV IG. POSSIBILITIES OF A COMBINATION OF DOCETAXEL WITH ANDROGEN DEPRIVATION IN INITIAL THERAPY OF HORMONESENSITIVE PROSTATE CANCER. Meditsinskiy sovet = Medical Council. 2017;(6):94-97. (In Russ.) https://doi.org/10.21518/2079-701X-2017-6-94-97
Views:
645
Email this article 